Article
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Molecular cancer therapeutics - 1 Sept 2008
Zabludoff Sonya D, Deng Chun, Grondine Michael R, Sheehy Adam M, Ashwell Susan, Caleb Benjamin L, Green Stephen, Haye Heather R, Horn Candice L, Janetka James W, Liu Dongfang, Mouchet Elizabeth, Ready Shannon, Rosenthal Judith L, Queva Christophe, Schwartz Gary K, Taylor Karen J, Tse Archie N, Walker Graeme E, White Anne M
Abstract excerpt
Insights from cell cycle research have led to the hypothesis that tumors may be selectively sensitized to DNA-damaging agents resulting in improved antitumor activity and a wider therapeutic margin. The theory relies on the observation that the majority of tumors are deficient in the G1-DNA damag...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.